Pasithea Therapeutics (KTTA) Common Equity (2020 - 2026)

Pasithea Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $54.8 million for Q1 2026.

• In Q1 2026, Common Equity rose 322.32% year-over-year to $54.8 million; the TTM figure through Mar 2026 stood at $54.8 million (up 322.32% YoY), while the FY2025 annual figure was $55.2 million, up 273.54% from the prior year.
• Common Equity came in at $54.8 million for Q1 2026 at Pasithea Therapeutics, down from $55.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $55.2 million in Q4 2025 to a low of $12.2 million in Q3 2025.
• A 5-year average of $31.5 million and a median of $28.4 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 10817.73% in 2022 and slumped 54.55% in 2024, its largest moves.
• Pasithea Therapeutics' Common Equity stood at $42.5 million in 2022, then tumbled by 44.94% to $23.4 million in 2023, then sank by 36.82% to $14.8 million in 2024, then surged by 273.54% to $55.2 million in 2025, then declined by 0.74% to $54.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $54.8 million, $55.2 million, and $12.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison